Navigation Links
Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30'
Date:10/9/2007

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, today announced that Andrea Matthews (age 25), manager of its Scientific Programs, was selected by Mass High Tech for its "People to Watch Under 30."

"We are proud to have a young, successful individual like Andrea as part of our team," said Dr. Keith O. Elliston, president and CEO at Genstruct. "She has been a go-getter ever since she started at Genstruct during college. With her strong business, technology and scientific acumen, Andrea serves as a valued translator between our scientific and development teams. She not only shows significant initiative in advancing her career, but also excels in her personal life by volunteering to help Cambridge-area youth and competing in triathlons."

Ms. Matthews received her B.A. cum laude in biochemistry and molecular biology from Boston University in 2004. As an undergraduate summer student, she began working at Genstruct as the first full-time female employee for the company and the youngest by more than 10 years.

In her role as the manager of Scientific Programs at Genstruct, Ms. Matthews drives the progress of scientific and technology development for the company by prioritizing and managing requests across all of its pharmaceutical research projects. During her four years at Genstruct, she has presented scientific information and successfully gone head-to-head with scientists with more than 20 years of experience.

About Genstruct

Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact:

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. San Diego firm selected for Madison Wi-Fi project
2. Milwaukee-based eFilm software selected by InSight Health, announces Workstation upgrade
3. Berbee Selected by Microsoft as Featured Speaker for New Product Launch
4. Can sales outsourcing grow Wisconsin biotechs?
5. Wisconsin biotechs plan Japan trade mission
6. Madison biotechs get Commerce grants
7. Midwest shares in stock-market bloodshed as biotechs falter
8. Technology helps but the best way to reduce Sarbox cost is with people
9. Age of empowered individuals: People power behind robust computing
10. Two-week notices: People are still concerned
11. Power for the people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 ... the "Company"), a biopharmaceutical company focused on the development and ... present at the 18 th Annual BIO CEO ... 10:00 a.m. EST in New York, NY ... CEO, will provide an update on the ongoing clinical trial ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... , Feb. 3, 2016  With the growing ... cliff that is underway, therapies such as monoclonal ... a whole host of indications are in high ... in the development and production of these therapeutics. ... quality and high costs, novel approaches and novel ...
(Date:2/3/2016)... ... February 03, 2016 , ... ProMIS Neurosciences ... targets (epitopes) specific to misfolded, propagating strains of Amyloid beta involved in Alzheimer’s ... therapeutics for Alzheimer’s. , Following on from the first misfolded Amyloid beta target ...
Breaking Biology Technology:
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... Jan. 11, 2016  higi, the leading retail ... retail locations, web and mobile, today announced it ... from existing investors. --> ... to further innovate higi,s health platform – its ... portal – including expanding services and programs to ...
Breaking Biology News(10 mins):